Altimmune, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $41,000 | $20,000 | $426,000 | -$68,000 | $4.4M |
| Operating income | -$94.5M | -$103.2M | -$95.9M | -$87.7M | -$96.9M |
| Operating expenses | $94.5M | $103.2M | $96.4M | $87.7M | $101.3M |
| Cash from operations | -$67.5M | -$79.8M | -$75.8M | -$62.6M | -$78.2M |
| Capital expenditure | $11,000 | — | $47,000 | $126,000 | $12.1M |
| Free cash flow | -$67.5M | — | -$75.9M | -$62.7M | -$90.4M |
| Impairments | $0 | $0 | $0 | — | $0 |
| Total assets | $279.9M | $139.3M | $210.6M | $206.9M | $218.9M |
| Total liabilities | $55.0M | $15.8M | $16.5M | $21.6M | $19.7M |
| Total debt | $35.0M | — | — | — | — |
Shares outstanding 194.5M · Free float 89.5%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.